Data sharing is key to quickly identify and respond to zoonotic diseases
Luheshi et al 15 - Junior Associate Fellow at Centre for Science and Policy, University of Cambridge; Dr Sobia Raza is a Data Science Policy Analyst at the PHG Foundation; Sharon J. Peacock is at the Department of Medicine, University of Cambridge, Genome Medicine
(Leila, “Moving pathogen genomics out of the lab and into the clinic: what will it take?”, 12/30/15, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697326/)
Pathogen genomics is a team game The most successful demonstrations of the capabilities of pathogen genomics were the deciphering of the origins of the Middle East respiratory syndrome coronavirus and the management of the Europe-wide 2011 STEC outbreak. These have also been excellent examples of the effectiveness of collaborations, which were supported by openness and data sharing, that span multiple geographies, fields of expertise and professional groups. As we move towards implementing these advances across entire health systems, this collaborative spirit needs to be harnessed and scaled up to deliver more formalised networks for sharing knowledge and best practice. These networks will expedite national service deployment, accelerate future service development and provide expert forums in which the arduous but essential task of establishing the standards and benchmarks of service quality can be undertaken. High-level strategic coordination and knowledge-sharing across health delivery organisations are equally essential. For example, synergy in the development of pathogen genomics programmes across animal and human health sectors will be needed to deliver a ‘one-health’ approach to tackling many of the most pressing zoonotic disease threats, such as avian influenza and the spread of antimicrobial resistance from livestock to humans, as well as the more commonplace but persistent issue of foodborne illnesses. Data — it’s time to go big No large-scale genomics enterprise can hope to succeed without effective data integration and sharing. In the case of pathogen genomics for clinical or public health, data integration will require the construction of dedicated infrastructure (real or virtual) to collate, store, analyse and share genomic, epidemiological and clinical data across complex national and international health systems. This integration will be particularly crucial to enable the delivery of genomic epidemiology services, in which the requirement for data sharing across locations is fundamental and time (as in the 2015 Ebola outbreak) is very much of the essence. Data integration and access will become equally central in diagnostic microbiology, where having an accurate and readily accessible summary of genotype, phenotype and clinical information for different pathogens is essential to deliver care to patients. Notably, the Global Microbial Identifier (http://www.globalmicrobialidentifier.org/Workgroups#work-group-1) and the Global Alliance for Genomic Health (https://genomicsandhealth.org/node/12703) projects are already demonstrating that huge technical, regulatory and political efforts will be required to overcome barriers imposed by the varying capabilities, legal systems and cultural frameworks of different nations if transnational genomic and clinical data integration is to be achieved. As an example, such barriers led the Indonesian government to temporarily withdraw from the Global Influenza Surveillance Network in 2007, owing to concerns that, if data were shared, proprietary interests would be exerted over the H5N1 strains [9]. The same issues can also impose barriers to sharing and data integration within individual health systems. Staying ahead of the game The application of genomics to infectious disease management is still in its infancy, and we currently lack the background knowledge, as well as the technological capability, to deliver rapid, clinically actionable information based on genomic analysis that can improve outcomes for patients. This situation is fluid, as sequencing technology (in the form of devices that are increasingly more portable, cost less and have a longer read capability) and analysis (in the form of cloud computing, more efficient metagenomic analysis and implementation of automated analytic pipelines) continue to develop apace. However, capitalising on the current rapid pace of innovation will demand novel approaches to public–private cooperation and co-development of the type seen with the Oxford Nanopore Minion Access Programme, which puts new genomic technology in the hands of its users (including those in the health system) at the earliest possible opportunity [10]. These efforts will also benefit from building on the commendably open and collaborative approaches for the development of knowledge and analytical methods that are already being taken by many pathogen genomics researchers. These collaborations will ensure that the knowledge and expertise of these researchers are shared rapidly with the clinical and public-health communities in which their influence is most needed.